Rheumatoid Arthritis
Join us in a study designed to learn more about a new treatment for rheumatoid arthritis (RA). This study has two parts: Part A includes 5 different treatment groups, and Part B focuses on one group. We want to understand how safe and effective this treatment is for adults with moderate to severe RA.
Study site: NeoClinical Research
- Rheumatoid arthritis
- About the Study
- This study is focused on understanding a new treatment for rheumatoid arthritis (RA). Here are some important points: * The study lasts up to 64 weeks. * Treatment phases may last up to 6 months. * Part A includes 10 visits, and Part B includes 13 visits, both with follow-ups after treatment. By participating, you could contribute to important research that may benefit others living with RA.
- What does the study involve?
- The treatment involves an injection, which can be given either under the skin or directly into the vein.
What to expect
- Placebo
- Everyone receives an active treatment.
- Which treatment you get
- Chosen at random, and you'll know which treatment you get.
- Who can participate?
- We're looking for adults aged 18 and older with a diagnosis of rheumatoid arthritis for at least 3 months. You should be experiencing moderate to severe symptoms and may have had trouble with other RA treatments. Think you might qualify? Apply to find out!
Where is the study taking place?
Palmetto Medical Plaza
Study details
- Sponsor
- Sanofi
- Phase
- Phase 1/Phase 2: testing whether it works, and its safety, in a larger group
- Dates
- July 2026 to October 2028 (expected)
- Size
- 140 participants across all sites
- Healthy volunteers
- Only people with the condition
Study details are from ClinicalTrials.gov. The rest of this page is written by the study site for patients and may summarize or reword the registry record, which is the official text. A study listed on ClinicalTrials.gov has not necessarily been reviewed or approved by the U.S. government.
About NeoClinical Research
NeoClinical Research is a leading, multi-therapeutic clinical research center based in South Florida that bridges the gap between leading pharmaceutical companies and diverse patient populations.